Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy
Australia now open for study of rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Australia and SAN FRANCISCO, Oct. 13, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received approval in Australia from...
3M V.A.C. Therapy negative pressure wound therapy achieves key medical evidence milestone, surpassing 2,000 peer-reviewed medical journal studies published
ST. PAUL, Minn., Oct. 13, 2022 /PRNewswire/ -- 3M Health Care's Medical Solutions Division today announced its 3M™ V.A.C.® Therapy negative pressure wound therapy (NPWT) has surpassed a clinical evidence milestone of 2,000 published, peer-reviewed medical journal studies. V.A.C. Therapy is the first and only NPWT solution to garner this number of published...
First in North America: Jolly Good Hosts Clinical VR Multi Seminar in Boston, Aiming for Mass Production of UGC Medical VR
At the Boston Convention Center on Tuesday, October 25, 2022 TOKYO, Oct. 13, 2022 /PRNewswire/ -- Jolly Good Inc. (Chuo-ku, Tokyo, CEO: Kensuke Joji, hereinafter referred to as "Jolly Good") will hold a large-scale seminar on clinical training VR produced by the UGC* medical VR platform "JOLLYGOOD+" (Jolly Good Plus) on Tuesday, October 25, 2022, in Boston in the U.S....
Research Collaboration between Prof. Antonio Gasbarrini team at Gemelli Hospital and Asian Biotech companies, Coree and Dx&Vx
SEOUL, South Korea, Oct. 13, 2022 /PRNewswire/ -- According to International Diabetes Federation, approximately 537 million adults (20-79 years) are living with diabetes worldwide and 206 million adults of the Western Pacific region including China, Japan, and South Korea have diabetes in 2021. Studies have shown that Asians are at higher risk of developing type 2 diabetes compared with...
Neurophth Therapeutics Conducts Special Interview with Dr. Satoshi Kashii on World Sight Day
WUHAN, China and SAN DIEGO, Calif., Oct. 13, 2022 /PRNewswire/ -- October 13th is World Sight Day. Today, Neurophth Therapeutics, Inc. has a special interview with Dr. Satoshi Kashii, Professor of Visual Sciences and Ophthalmology, Aichi Shukutoku University, President of Asian Neuro-Ophthalmology Society, to understand his perspectives on LHON. LHON is...
Menarini Silicon Biosystems’s CELLSEARCH® CMMC and HER2-CTC Liquid Biopsy Tests obtain Reimbursement Codes with Preliminary Pricing Determination
These new codes are required to access Medicare/Medicaid insurance reimbursement for novel CELLSEARCH Circulating Multiple Myeloma Cell (CMMC) and HER2 Circulating Tumor Cell (CTC-HER2) assays, to monitor disease status in patients with life-threatening illnesses. HUNTINGDON VALLEY, Pa., Oct. 13, 2022 /PRNewswire/ -- Menarini Silicon Biosystems (MSB), Inc. is announcing that the AMA...
Galderma announces intention to expand manufacturing and innovation footprint in Asia-Pacific
Galderma, the pure-play dermatology category leader, announces its intention to explore opportunities to build its fifth manufacturing plant in Singapore Supported by the Singapore Economic Development Board, the new facility is expected to increase Galderma's manufacturing capacity by up to 350 million units per year, in response to continuing demand for premium science-based products in the Dermo‑cosmetics sector...
Harbour BioMed Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Oct. 13, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, announced today that the Company will present new preclinical data of five portfolio assets...
Samsung Biologics obtains three global ISO certifications
Receives accreditation for information security management system, information security in cloud services, and anti-bribery management systems First global CDMO to be ISO 27001 and ISO 27017 certified Earns Excellence Award for Integrated Management System from BSI for its performance INCHEON, South Korea, Oct. 13, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization...
Alex Therapeutics presents results from digital therapeutic pilot study showing nearly 50% reduction in anxiety
The Digital Therapeutic (DTx) was developed by DTx leader Alex Therapeutics using the proprietary "Alex DTx Platform" in partnership with Vicore Pharma In the study patients with Idiopathic Pulmonary Fibrosis (IPF) and anxiety were given the DTx Safety, functionality, and user experience were all studied and found positive Average reduction in anxiety, GAD-7*, was 4.2 points Pivotal phase...
